|
| 36082904 | Comprehensive Landscape of Cyclin Pathway Gene Alterations and Co-occurrence with FGF/FGFR Aberrations Across Urinary Tract Tumors. | Oncologist | 2023 |
| 35176763 | The Genomics of Colorectal Cancer in Populations with African and European Ancestry. | Cancer Discov | 2022 |
| 35584350 | Clustered 8-Oxo-Guanine Mutations and Oncogenic Gene Fusions in Microsatellite-Unstable Colorectal Cancer. | JCO Precis Oncol | 2022 |
| 35705558 | Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. | Nat Commun | 2022 |
| 35580297 | AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations. | J Clin Oncol | 2022 |
| 35970994 | Activating IGF1R hotspot non-frameshift insertions define a novel, potentially targetable molecular subtype of adenoid cystic carcinoma. | Mod Pathol | 2022 |
| 36050473 | Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers. | Nature | 2022 |
| 36253270 | A Common Cell of Origin for Inflammatory Myofibroblastic Tumor and Lung Adenocarcinoma with ALK rearrangement. | Clin Lung Cancer | 2022 |
| 35176763 | The Genomics of Colorectal Cancer in Populations with African and European Ancestry. | Cancer Discov | 2022 |
| 31412008 | Comprehensive Genomic Profiling of Adult Renal Sarcomas Provides Insight into Disease Biology and Opportunities for Targeted Therapies. | Eur Urol Oncol | 2021 |
| 33522043 | Landscape of Cyclin Pathway Genomic Alterations Across 5,356 Prostate Cancers: Implications for Targeted Therapeutics. | Oncologist | 2021 |
| 33654076 | Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting. | Nat Commun | 2021 |
| 33542076 | Optimized EGFR Blockade Strategies in <i>EGFR</i> Addicted Gastroesophageal Adenocarcinomas. | Clin Cancer Res | 2021 |
| 33542076 | Optimized EGFR Blockade Strategies in <i>EGFR</i> Addicted Gastroesophageal Adenocarcinomas. | Clin Cancer Res | 2021 |
| 33775530 | Comprehensive genomic profiling of metastatic collecting duct carcinoma, renal medullary carcinoma, and clear cell renal cell carcinoma. | Urol Oncol | 2021 |
| 34950838 | Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti-PD-1 Therapy. | JCO Precis Oncol | 2021 |
| 34463133 | Real-world association of HER2/<i>ERBB2</i> concordance with trastuzumab clinical benefit in advanced esophagogastric cancer. | Future Oncol | 2021 |
| 34476330 | Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma. | JCO Precis Oncol | 2021 |
| 34077268 | Clinicopathologic Features and Response to Therapy of <i>NRG1</i> Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. | J Clin Oncol | 2021 |
| 34215504 | Comprehensive genomic profiling of histologic subtypes of urethral carcinomas. | Urol Oncol | 2021 |
| 34333275 | Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors. | Transl Oncol | 2021 |
| 32061548 | Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile. | Eur Urol Oncol | 2021 |
| 32918774 | Targetable BRAF and RAF1 Alterations in Advanced Pediatric Cancers. | Oncologist | 2021 |
| 32861617 | Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma. | Eur Urol Focus | 2021 |
| 32885893 | Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large-Scale Data to Inform Therapeutic Directions. | Oncologist | 2021 |
| 32516377 | Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer. | J Natl Cancer Inst | 2021 |
| 31578273 | Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence. | Oncologist | 2020 |
| 31959546 | Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder. | Eur Urol | 2020 |
| 31988001 | Clinicopathologic Characteristics of BRG1-Deficient NSCLC. | J Thorac Oncol | 2020 |
| 31985116 | Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions. | BJU Int | 2020 |
| 31882336 | Squamous Transformation of Prostate Adenocarcinoma: A Report of Two Cases With Genomic Profiling. | Clin Genitourin Cancer | 2020 |
| 31882281 | Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. | Eur Urol | 2020 |
| 31708296 | Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. | Eur Urol | 2020 |
| 33046892 | Targetable gene fusions and aberrations in genitourinary oncology. | Nat Rev Urol | 2020 |
| 33097651 | Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. | ESMO Open | 2020 |
| 32966992 | Characterization of Clinical Cases of Malignant PEComa via Comprehensive Genomic Profiling of DNA and RNA. | Oncology | 2020 |
| 32823229 | Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling. | Lung Cancer | 2020 |
| 32903788 | Pan-Cancer Analysis of <i>BRCA1</i> and <i>BRCA2</i> Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity. | JCO Precis Oncol | 2020 |
| 32393201 | Recurrent secondary genomic alterations in desmoplastic small round cell tumors. | BMC Med Genet | 2020 |
| 32144050 | Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study. | Clin Genitourin Cancer | 2020 |
| 32464188 | Clinical and Genomic Characteristics of Small Cell Lung Cancer in Never Smokers: Results From a Retrospective Multicenter Cohort Study. | Chest | 2020 |
| 32399016 | Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation. | Case Rep Oncol | 2020 |
| 32368168 | Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the <i>ALK</i> Gene Have Durable Responses to ALK Kinase Inhibitors. | Lung Cancer (Auckl) | 2020 |
| 32156473 | Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss. | Gynecol Oncol | 2020 |
| 30025711 | Genomic Characterization of Testicular Germ Cell Tumors Relapsing After Chemotherapy. | Eur Urol Focus | 2020 |
| 31604903 | The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. | Oncologist | 2020 |
| 30380541 | A Pan-Cancer Landscape Analysis Reveals a Subset of Endometrial Stromal and Pediatric Tumors Defined by Internal Tandem Duplications of BCOR. | Oncology | 2019 |
| 35100719 | Atypical <i>RAS</i> Mutations in Metastatic Colorectal Cancer. | JCO Precis Oncol | 2019 |
| 35100719 | Atypical <i>RAS</i> Mutations in Metastatic Colorectal Cancer. | JCO Precis Oncol | 2019 |
| 35100669 | Acquired <i>CTNNB1</i> Mutation Drives Immune Checkpoint Inhibitor-Acquired Resistance in a Microsatellite Instability-High Gastroesophageal Adenocarcinoma With Brain Metastases. | JCO Precis Oncol | 2019 |